ArticleHuman vaccines & immunotherapeutics2026
RSV vaccine uptake among Medicare Advantage enrollees: August 2023 to December 2024.
Article in Human vaccines & immunotherapeutics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Respiratory syncytial virus (RSV) is one of the most common causes of respiratory tract infections, disproportionately affecting young children, older adults, and those with chronic medical conditions. In the US, RSV vaccine recommendations by the US Centers for Disease Control (CDC) for adults were first issued in 2023 and have since evolved. Uptake of the RSV vaccine by eligible US adults has been slower than expected, with approximately one-fifth (21.0%) of adults aged ≥ 65 years enrolled in Medicare fee-for-service plans receiving the vaccine in the first season of availability. We analyzed RSV vaccine uptake over two seasons among older adults enrolled in Medicare Advantage. Overall RSV vaccine uptake was higher in the 2023/2024 season compared with the 2024/2025 season, peaking in October of both years. Adults ≥ 75 years had higher vaccine uptake than those 65-74 years. Vaccination was highest among groups at increased risk for severe RSV illness. Among approximately 1.7 MM individuals who met the 2024 CDC recommendations for vaccination, roughly 80% did not have evidence of RSV vaccination. Targeted strategies are needed to further reach adults who are at increased risk for severe RSV illness.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.